Kliničke studije za Лупус u državi Ilinois
14 studija za Лупус traži učesnike na lokacijama u državi Ilinois.
Gradovi u državi Ilinois
Zvanični tekst studije (na engleskom)
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 13. 11. 2026. · NCT07430306Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Willow Rheumatology Wellness, Willowbrook
Тражи се учесникФаза 3
Узраст од 12 до 100 · Оба пола · Ажурирано 9. 11. 2026. · NCT06133972A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 3. 11. 2026. · NCT07438496A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
Тражи се учесникОпсервациона студија
Узраст 16 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07175285A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Тражи се учесникФаза 1
Узраст од 18 до 74 · Оба пола · Ажурирано 2. 11. 2026. · NCT07085104A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
Тражи се учесникФаза 3
Узраст 16 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06617325A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 26. 10. 2026. · NCT06925542A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 20. 10. 2026. · NCT07607964RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center - Accepting Adult and Adolescent Patients, Chicago
Тражи се учесникФаза 1/2
Узраст од 12 до 65 · Оба пола · Ажурирано 6. 10. 2026. · NCT06121297An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
Тражи се учесникФаза 3
Узраст од 5 до 17 · Оба пола · Ажурирано 30. 9. 2026. · NCT05835310A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
Тражи се учесникФаза 2
Узраст од 16 до 70 · Оба пола · Ажурирано 17. 9. 2026. · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
Тражи се учесникФаза 1/2
Узраст од 18 до 70 · Оба пола · Ажурирано 10. 9. 2026. · NCT06897930A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 10. 8. 2026. · NCT06977724Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
Тражи се учесникОпсервациона студија
Узраст од 18 до 110 · Оба пола · Ажурирано 15. 4. 2026. · NCT05934149Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.